SecBot SecBot
PRESS-RELEASE ·Filed May 27, 2026

MYGN

Myriad Genetics, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

This is a clinical data update with no near-term revenue catalyst. Monitor for potential biopharma partnership announcements or reimbursement developments following the ASCO presentations. The 97% detection rate and ultrasensitive range data are positive for the test's clinical positioning but do not change the near-term financial outlook.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.93
T+0 close · May 27, 2026 · via day close
Latest settled
−18.07%
T+60 · $3.22
Vs SPY
−19.95%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 27 $3.93entry
  2. T+1 · 6mo ago +7.38%α +6.83% · $4.22
  3. T+5 · 6mo ago +9.67%α +8.46% · $4.31
  4. T+20 · 5mo ago +38.17%α +40.07% · $5.43
  5. T+60 · 3mo ago −18.07%α −19.95% · $3.22
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Myriad Genetics announced it will present data at ASCO 2026 showing its Precise MRD test achieved 97% baseline detection across multiple cancer types in the MONSTAR-SCREEN-3 study, with 16% of samples detected at ultrasensitive levels. The data supports the clinical utility of the test for recurrence monitoring, but this is a scientific conference presentation with no immediate revenue or regulatory catalyst.

Key Facts

  • Precise MRD test achieved 97% baseline ctDNA detection in MONSTAR-SCREEN-3 pan-cancer analysis
  • 16% of samples detected in the ultrasensitive range
  • ctDNA-positive patients at 1-month post-surgery had significantly worse disease-free survival
  • Data presented across six posters at ASCO 2026 covering gastric, ovarian, head/neck, sarcoma, and pan-cancer indications
  • No financial terms, revenue guidance, or regulatory milestones disclosed in the press release

Financial Impact

No financial figures disclosed; the press release is a scientific data update with no immediate revenue or cost impact

Risk Factors

  • No revenue or regulatory milestones announced; commercialization timeline for Precise MRD remains uncertain
  • Competitive MRD tests from Guardant Health, Natera, and others may limit market share

Market Snapshot

Exchange
Nasdaq
Sector
In Vitro & In Vivo Diagnostic Substances
Analyst Consensus
12% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3302066

Track record

16 reports on MYGN

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +13.54% at T+5 after the Oct 20, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry price pending
  2. Nov 9, 20267d ago 8-K Neutral 2/10 Entry $5.67 to $5.72 Now $5.57 −1.76% ▲ +0.88% −0.44% vs SPY
  3. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $6.29 to $5.92 Now $5.57 −11.45% ▼ −5.88% −6.19% vs SPY
  4. Nov 4, 202612d ago 8-K Mixed 6/10 Entry $6.29 to $5.92 Now $5.57 −11.45% ▼ −5.88% −6.19% vs SPY
  5. Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $6.02 to $6.29 Now $5.57 −7.48% ▲ +4.49% +8.89% vs SPY
  6. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $6.63 to $6.67 Now $5.57 −15.99% ▲ +0.60% +0.99% vs SPY
  7. Oct 20, 202627d ago 8-K Bullish 7/10 Entry $5.54 to $5.57 Now $5.57 +0.54% ▲ +0.54% +0.02% vs SPY
  8. Oct 15, 20264w ago Press Release Neutral 1/10 Entry $3.98 Now $5.57 +39.95% No price data
  9. Oct 9, 20265w ago 8-K Neutral 3/10 Entry $4.20 to $4.08 Now $5.57 +32.62% ▼ −2.86% −2.85% vs SPY
  10. Sep 16, 20268w ago 8-K Neutral 3/10 Entry $3.86 to $4.14 Now $5.57 +44.30% ▲ +7.25% +6.12% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (11h 3m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 27, 2026